Blood Grouping: ABO, Rh(D), Antigens, Antibodies and Testing

Blood Grouping: ABO, Rh(D), Antigens, Antibodies, Testing and Clinical Significance

Study level: Clinical medicine, emergency medicine and pathology | Topic: Hematology and transfusion medicine

Learning objectives

• Explain ABO antigen inheritance and naturally occurring antibodies.
• Describe forward and reverse grouping, Rh(D) testing and antibody screening.
• Apply red-cell and plasma compatibility principles.
• Recognise blood-group discrepancies, weak D, Bombay phenotype and mixed-field reactions.
• Explain Rh alloimmunisation and haemolytic disease of the fetus/newborn.

1. Antigens and antibodies

A red-cell antigen is a genetically determined surface structure that may be recognised as foreign. A plasma antibody binds a specific antigen and can activate complement, cause agglutination or promote phagocytosis. A person normally lacks the ABO antigen(s) they do not express and may have the corresponding antibody.

ABO group	RBC antigen(s)	Expected plasma antibodies
A	A	Anti-B
B	B	Anti-A
AB	A and B	Neither anti-A nor anti-B
O	Neither A nor B	Anti-A and anti-B

ABO antibodies are mainly IgM and activate complement strongly, so an incompatible RBC transfusion can cause rapid intravascular haemolysis. ABO antibodies may also include IgG components and vary with age, illness and immune status.

2. ABO genetics and biochemistry

• The H gene creates the H substance on which A or B transferases act.
• The A allele adds N-acetylgalactosamine; the B allele adds galactose; O generally produces an inactive transferase.
• A and B are codominant; O is recessive. Genotype and phenotype are not always interchangeable because rare variants exist.
• Secretor status determines whether soluble ABO substances appear in saliva and other secretions.
• The rare Bombay (Oh) phenotype lacks H substance, so routine typing may appear group O but anti-H prevents safe transfusion with ordinary O blood; compatible Bombay units are required.

3. How blood grouping is performed

3.1 Forward (cell) grouping

Patient red cells are mixed separately with anti-A, anti-B and often anti-A,B reagents. Agglutination indicates the corresponding antigen on the RBC surface.

3.2 Reverse (serum/plasma) grouping

Patient plasma is mixed with known A1 and B reagent cells. Agglutination indicates the corresponding antibody in plasma. Reverse grouping confirms forward grouping and helps detect errors or weak/absent antibodies.

Forward result	Reverse result	Interpretation
Anti-A positive, anti-B negative	A1 cells negative, B cells positive	Group A.
Anti-A negative, anti-B positive	A1 cells positive, B cells negative	Group B.
Anti-A and anti-B positive	A1/B cells negative	Group AB.
Anti-A and anti-B negative	A1/B cells positive	Group O.

3.3 Rh(D) typing

Patient cells are tested with anti-D reagent. A positive result is Rh(D)-positive; a negative result is Rh(D)-negative under the laboratory method. Weak D or partial D variants may require additional testing and specialist interpretation, especially in pregnancy and transfusion.

4. ABO/Rh compatibility

4.1 Red-cell compatibility

Recipient	Usually compatible RBC groups	Reason
A positive	A positive/negative or O positive/negative, after testing.	Recipient anti-B must not meet B antigen.
B positive	B positive/negative or O positive/negative, after testing.	Recipient anti-A must not meet A antigen.
AB positive	ABO/Rh-compatible units; often broadest RBC receiving options.	No anti-A/anti-B, but other antibodies still matter.
O negative	O negative RBCs preferred.	Anti-A/anti-B in plasma; Rh-negative recipient needs Rh-negative red cells.

“Universal donor” and “universal recipient” are emergency shorthand, not substitutes for a full type-and-screen/cross-match. O-negative supply is limited and should be reserved according to local policy. In life-threatening bleeding, uncrossmatched group O or group-specific blood may be released by the blood bank while testing continues.

4.2 Plasma compatibility

For plasma, the donor’s antibodies matter. AB plasma lacks anti-A and anti-B and is broadly compatible as donor plasma; group O plasma contains both antibodies and is not universal plasma. The exact product choice follows the blood bank’s policy, especially in massive transfusion.

5. Rh system and alloimmunisation

• Rh proteins are inherited membrane antigens; D is the most immunogenic.
• Unlike ABO antibodies, anti-D is not naturally present. It develops after exposure through transfusion or fetomaternal haemorrhage.
• Anti-D is usually IgG, crosses the placenta and can cause fetal/neonatal haemolysis.
• Rh-negative pregnant patients require antenatal antibody screening and prophylaxis with anti-D immunoglobulin according to local obstetric protocol after sensitising events and at recommended gestations.
• Once immune anti-D is present, prophylaxis does not remove it; monitor the pregnancy and fetus with specialist care.

6. Other clinically important blood-group systems

System	Clinical significance
Kell	Highly immunogenic; anti-K can cause severe transfusion reactions and haemolytic disease of the fetus/newborn.
Kidd	Antibodies may become undetectable and cause delayed haemolysis after re-exposure.
Duffy	Anti-Fya/Fyb can cause transfusion reactions and HDFN; Duffy-null phenotype has malaria relevance.
MNS	Some antibodies are clinically significant, especially after repeated exposure.
Lewis/P systems	Often less clinically significant, but interpretation depends on antibody class, temperature and patient context.

Patients with chronic transfusion needs, multiple antibodies or haemoglobinopathy may require extended phenotype/genotype matching to reduce alloimmunisation.

7. Blood-group discrepancy

A discrepancy is any conflict between forward and reverse grouping, current and historical result, or expected and observed reaction. Never release routine blood until resolved unless an emergency-release protocol is authorised.

Cause	Clue	Action
Clerical/identification error	Unexpected result or mismatch with history.	Stop, redraw correctly labelled sample and investigate identity.
Weak/missing antibodies	Newborn, elderly, immunosuppressed or hypogammaglobulinaemic patient.	Use extended testing and specialist interpretation.
Weak/variant antigen	Weak or mixed-field forward reaction.	Repeat with alternate reagents, anti-A1 lectin or reference laboratory.
Recent transfusion/transplant	Two RBC populations or mixed-field agglutination.	Review transfusion/transplant history; genotype may help.
Cold autoantibody/rouleaux	Panagglutination or pseudoagglutination.	Warm technique, saline replacement or specialised testing.
Rare phenotype (e.g., Bombay)	Appears O but reacts with anti-H or has unexpected antibodies.	Reference laboratory and rare-donor search.

8. Haemolytic disease of the fetus and newborn (HDFN)

Maternal IgG crosses the placenta and destroys fetal RBCs when maternal antibodies target fetal antigens. Anti-D is classic, but anti-c, anti-K and other antibodies can be severe.

• Screening: maternal ABO/Rh type and antibody screen early in pregnancy and at recommended intervals.
• Risk assessment: identify antibody specificity and titre/quantitation; paternal/fetal antigen status and previous affected pregnancy influence risk.
• Monitoring: specialist ultrasound and fetal middle cerebral artery Doppler detect fetal anaemia; severe disease may require intrauterine transfusion.
• Newborn evaluation: neonatal blood group, DAT, Hb and bilirubin; treat anaemia and hyperbilirubinaemia promptly.

9. Specimen and bedside safety

• Use two patient identifiers; never pre-label tubes away from the bedside.
• Record transfusion/pregnancy history, previous antibodies and special requirements.
• Draw pre-transfusion samples before emergency blood whenever possible.
• Compare current group with historical results; unexplained discrepancy is a safety stop.
• Document emergency-release blood and switch to fully tested compatible units as soon as available.

10. Clinical cases

Case 1: wrong blood risk

A trauma patient has no reliable identity and needs immediate RBCs. Use the local emergency-release protocol, usually uncrossmatched group O, obtain a correctly labelled sample immediately and transition to group-specific/crossmatched units when safe. Never assume the patient’s stated group without laboratory confirmation.

Case 2: forward/reverse mismatch

Forward typing suggests group A, but reverse typing shows weak reactions with both A1 and B cells. Consider weak antibodies, recent transfusion, cold interference or an A subgroup; investigate with the transfusion laboratory before routine release.

Case 3: pregnant Rh-negative patient

An Rh-negative pregnant patient has vaginal bleeding. Perform antibody screening and urgently contact obstetrics; anti-D prophylaxis timing and dose follow local guidelines and depend on gestation and fetomaternal haemorrhage.

11. Quick self-test

1. What is the difference between forward and reverse grouping?
2. Why is ABO-incompatible RBC transfusion so dangerous?
3. Why can anti-D cause fetal disease?
4. Which blood component is governed by donor antibodies rather than donor RBC antigens?
5. What should happen when a current result conflicts with historical blood group?

Answers

1. Forward tests patient RBC antigens; reverse tests patient plasma antibodies against known reagent cells.
2. IgM anti-A/anti-B activates complement and causes rapid intravascular haemolysis, shock, DIC and renal injury.
3. Anti-D is IgG, crosses the placenta and destroys fetal Rh(D)-positive RBCs.
4. Plasma; donor antibodies must be compatible with recipient RBC antigens.
5. Stop routine release, verify identity and repeat/resolve testing with the transfusion laboratory; use emergency-release protocol only if life-threatening.

Key take-home points

• ABO antigens are on RBCs; naturally occurring ABO antibodies are in plasma.
• Forward and reverse grouping must agree before routine transfusion.
• Rh(D) alloimmunisation is preventable and clinically important in pregnancy.
• Non-ABO antibodies can cause delayed haemolysis and HDFN; historical antibody records matter.
• When in doubt, stop and investigate—the safest blood group result is a verified result.

Selected references

• NCBI Bookshelf: Blood Groups and Red Cell Antigens
• NCBI Bookshelf: ABO Blood Group System
• NCBI Bookshelf: Rh Blood Group System
• NCBI Bookshelf: Hemolytic disease of the newborn
• MedlinePlus: Red Blood Cell Antibody Screen